Sun Pharmaceutical Industries Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Dilip Shanghvi
Chief Executive Officer (CEO)
₹54.5m
Compensación total
| Porcentaje del salario del CEO | 75.2% |
| Permanencia del CEO | 31.1yrs |
| Participación del CEO | 9.6% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 2.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Apr 28Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?
Apr 09Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00
Feb 02Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?
Feb 02Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jan 19Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Dec 27Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly
Nov 04Here's Why I Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Oct 21Calculating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Sep 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Compensación vs. Mercado: La compensación total de Dilip($USD654.09K) está por debajo de la media de empresas de tamaño similar en el mercado Indian ($USD946.25K).
Compensación vs. Ingresos: La compensación de Dilip ha sido consistente con los resultados de la empresa en el último año.
CEO
Dilip Shanghvi (68 yo)
31.1yrs
Permanencia
₹54,534,909
Compensación
Mr. Dilip Shantilal Shanghvi serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He has been the Chairman of Sun Pharma Advanced Research Com...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹54.53m | 9.6% ₹ 350.1b | |
| Director of Corporate Development | no data | ₹65.30m | sin datos | |
| Chief Financial Officer | 6.8yrs | ₹38.89m | sin datos | |
| Executive Vice-President of Global Operations | no data | sin datos | sin datos | |
| EVP & Chief Information Officer | no data | sin datos | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Company Secretary & Compliance Officer | 2.3yrs | sin datos | sin datos | |
| Chief Human Resources Officer | less than a year | sin datos | sin datos | |
| Chief Executive Officer of India Business | no data | sin datos | sin datos | |
| Executive VP | no data | sin datos | 0.12% ₹ 4.4b | |
| Chief Executive Officer of North America Business | 7.7yrs | sin datos | sin datos | |
| Senior VP - Corporate Relations & CSR - India Regulatory Affairs | no data | sin datos | sin datos |
2.3yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SUNPHARMA se considera experimentado (2.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Executive Director | 31.1yrs | ₹54.53m | 9.6% ₹ 350.1b | |
| Executive VP | less than a year | sin datos | 0.12% ₹ 4.4b | |
| Non-Executive & Non-Independent Director | 30.3yrs | ₹1.90m | 1.8% ₹ 65.6b | |
| Non-Executive & Independent Director | 2.9yrs | ₹4.80m | sin datos | |
| Non-Executive Independent Director | 5.9yrs | ₹7.60m | 0.00033% ₹ 12.0m | |
| Independent Director | less than a year | sin datos | sin datos | |
| Lead Independent Director | 2.9yrs | ₹8.50m | sin datos | |
| Independent Director | 1.4yrs | ₹2.17m | sin datos |
2.9yrs
Permanencia media
66.5yo
Promedio de edad
Junta con experiencia: La junta directiva de SUNPHARMA no se considera experimentada (2.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.